Skip to content

Study of the Role of Hemostasis in Perioperative Anaphylaxis

Study of the Role of Hemostasis in Perioperative Anaphylaxis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04825158
Acronym
HEMOCANOPE
Enrollment
30
Registered
2021-04-01
Start date
2021-04-01
Completion date
2024-02-09
Last updated
2021-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaphylaxis, Hemoptysis, Perioperative Complication

Brief summary

Anaphylaxis is a severe and life-threatening complication during the perioperative period. Perioperative anaphylaxis is still associated with a significant mortality despite quick and efficient management using epinephrine, the mainstay of acute treatment. Experimental data and few case reports are suggesting that hemostasis, and more precisely platelets, could play a role in anaphylaxis. Our main hypothesis is that activation of the hemostatic system contributes to the severity of the reaction

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient, male or female, adult * In the perioperative period * In whom the diagnosis of anaphylactic shock is suggested * Patient is giving his consent to participate in the study

Exclusion criteria

* Subject under legal protection * Subject under guardianship or guardianship * Anemia less than 7 g /dl at the time of inclusion

Design outcomes

Primary

MeasureTime frameDescription
Platelet activationAs soon as possible after onset of anaphylaxisMeasurement of: Plasmatic serotonin level, Plasmatic PF-4 level, P-selectin expression (MFI, %), Platelet count

Contacts

Primary ContactCharles-Ambroise TACQUARD, PHD
charlesambroise.tacquard@chru-strasbourg.fr+333 69 55 16 08
Backup ContactXavier DELABRANCHE, PHD
Xavier.delabranche@chru-strasbourg.fr03.69.55.09.36

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026